On Tuesday, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) opened lower -0.09% from the last session, before settling in for the closing price of $715.13. Price fluctuations for REGN have ranged from $693.00 to $1211.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 19.99%. Company’s average yearly earnings per share was noted 2.79% at the time writing. With a float of $105.93 million, this company’s outstanding shares have now reached $108.30 million.
Considering the fact that the conglomerate employs 13450 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.42%, operating margin of 28.92%, and the pretax margin is 35.89%.
Regeneron Pharmaceuticals, Inc (REGN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Regeneron Pharmaceuticals, Inc is 3.61%, while institutional ownership is 85.68%. The most recent insider transaction that took place on Nov 01 ’24, was worth 844,610. In this transaction EVP Commercial of this company sold 1,000 shares at a rate of $844.61, taking the stock ownership to the 12,931 shares. Before that another transaction happened on Nov 01 ’24, when Company’s Officer proposed sale 1,000 for $844.61, making the entire transaction worth $844,610.
Regeneron Pharmaceuticals, Inc (REGN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 2.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.50% during the next five years compared to 10.31% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Check out the current performance indicators for Regeneron Pharmaceuticals, Inc (REGN). In the past quarter, the stock posted a quick ratio of 4.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.67. Likewise, its price to free cash flow for the trailing twelve months is 22.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 40.41, a number that is poised to hit 11.30 in the next quarter and is forecasted to reach 44.75 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
Compared to the last year’s volume of 0.57 million, its volume of 1.03 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 19.69%. Additionally, its Average True Range was 20.30.
During the past 100 days, Regeneron Pharmaceuticals, Inc’s (REGN) raw stochastic average was set at 4.14%, which indicates a significant decrease from 19.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.43% in the past 14 days, which was higher than the 27.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $814.19, while its 200-day Moving Average is $978.50. Nevertheless, the first resistance level for the watch stands at $720.93 in the near term. At $727.39, the stock is likely to face the second major resistance level. The third major resistance level sits at $734.78. If the price goes on to break the first support level at $707.08, it is likely to go to the next support level at $699.69. Should the price break the second support level, the third support level stands at $693.23.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Key Stats
There are currently 109,890K shares outstanding in the company with a market cap of 78.51 billion. Presently, the company’s annual sales total 13,117 M according to its annual income of 3,954 M. Last quarter, the company’s sales amounted to 3,721 M and its income totaled 1,341 M.
